ArticleAIDS research and therapy2025
Prevalence and factors associated with frailty among older adults with and without HIV in Kampala, Uganda.
Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Interventions and opportunities to enhance aging among people with HIV: a focus on frailty, sarcopenia, and intrinsic capacity.Topics in antiviral medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSub-Saharan Africa has the highest prevalence of older adults with HIV worldwide, a subgroup with an increased risk of incident age-related conditions, such as frailty. We investigated the prevalence and factors linked to frailty among older people (aged ≥ 60 years) with HIV (PWH) and age- and sex-matched people without HIV (PWOH) in Kampala, Uganda.
methodsFrailty was assessed using the frailty phenotype, proposed by Fried and colleagues, based on five criteria: unintentional weight loss, exhaustion, low physical activity, slowness, and weakness. We estimated the prevalence of frailty and pre-frailty and fitted a modified Poisson regression model to identify significantly associated factors.
resultsA total of 749 participants (371 PWH and 378 PWOH), 49.5% women, with a mean age of 67 (standard deviation 6.0) years. PWH had a median time of antiretroviral therapy (ART) use of 17 years (interquartile range 12-19), and 94.6% of PWH had viral suppression (viral load < 50 copies/ml). PWH had a similar prevalence of frailty (15.1% vs. 13.5%, P-value 0.53) and prefrailty (45.2% vs. 43.1%, P-value 0.55) compared to PWOH. Frailty was associated with older age, female sex, having no partner, being underweight, presenting food insecurity, and depressive symptoms.
conclusionIn our study, older PWH and PWOH had a similar prevalence of frailty and prefrailty. This unexpected result may be attributable to the benefits of ART and may reflect substantial improvements in the clinical management of PWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.